GETTYSBURG, Pa. (WHTM) – A potential breakthrough in the fight against cancer is taking place in Midstate. A Gettysburg doctor is the first in the world to use a new drug.
The drug from the biopharmaceutical company Theratechnologies has no name yet. At the moment, it is only referred to as TH1902 and is specifically targeted to receptors on cancer cells.
“So your target is a cancer cell. You have a guided missile, so it’s a drug that has some chemotherapy and now you’re going to apply it directly to your target, instead of affecting any other part of your body, ”said Dr. Satish Shah, Cancer Medical Director from Gettysburg Center.
This means that, in theory, the side effects of cancer treatment would be much less severe than things like radiation and chemotherapy. Dr. Shah gave the drug two weeks ago to Michael Snyder, who has prostate cancer. He’s the first patient to try.
“No significant side effects at this point that really interfere with my daily life and the things I do and I am very grateful for that part, because like I said, the last chemo really made me sick,” Snyder said.
The intravenous infusion takes about an hour and would be administered every three weeks.
“At the moment, it can be used for any solid tumor, so solid tumor anything like lung, colon, breast, prostate. These are very common cancers, but you can use for uterine, you can use for the ovary, ”said Dr. Shah.
The first phase of this clinical trial aims to find the right dosage. Later, the researchers will examine specifically how the drug affects different types of cancer.
If everything goes according to plan, abc27 News is informed that this treatment could be commercially available in two to five years.